Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BI-300202](https://pryzm-maps.s3.us-west-2.amazonaws.com/3052current_maps.png)
Countries in Clinic: Belgium, Germany
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
U1111-1299-6907 | P1 |
Recruiting |
Healthy Volunteers |
2024-09-27 |
28% |
U1111-1298-9134 | P1 |
Completed |
Healthy Volunteers |
2024-07-08 |
|
NCT05945888 | P1 |
Completed |
Healthy Volunteers |
2023-11-13 |
70% |